Supportive of this, intensified subcutaneous insulin therapy can improve metabolic control, return changes in the GH-IGF-axis towards normal and decrease progression of diabetes complications in patients with T1D [9]. The gene discussed is IGF1; the disease is type 1 diabetes mellitus.